A phase II, open-label, non-controlled, intrapatient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, relapsed or treatment naiive severe aplastic anemia or rec

Administered By

Awarded By

Contributors

Start/End

  • April 11, 2017 - December 31, 2024